Aelis Farma SA (AELIS.PA)
- Business Wire
Aelis Farma Announces the Last Patient, Last Visit in its Clinical Phase 2b Trial with AEF0117 for the Treatment of Cannabis Use Disorder
BORDEAUX, France, April 18, 2024--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases, is pleased to announce today a significant milestone in the clinical development of AEF0117: the last patient visit in the clinical phase 2b study, which included 333 individuals seeking treatment for cannabis use disorder (CUD), has been completed.
- Business Wire
Aelis Farma Reports Its 2023 Annual Financial Resultsand Confirms Its 2024 Outlook
BORDEAUX, France, April 02, 2024--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, today announces its full year results for the year to December 31, 2023.
- Business Wire
Aelis Farma Announces Its 2024 Financial Calendar
BORDEAUX, France, January 30, 2024--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases, today announces its indicative financial calendar for the financial year 2024.
